Loading...
XSES
42T
Market cap38mUSD
Sep 17, Last price  
0.05SGD
1D
-5.56%
1Q
-15.00%
Jan 2017
-66.00%
IPO
-83.55%
Name

Trendlines Group Ltd

Chart & performance

D1W1MN
XSES:42T chart
P/E
18.84
P/S
104.83
EPS
0.00
Div yield, %
Shrs. gr., 5y
2.78%
Rev. gr., 5y
-44.47%
Revenues
350k
-93.91%
13,768,00029,523,0005,952,0005,140,8005,611,6596,419,9886,678,2095,220,8086,627,4036,344,1102,374,000-20,988,0005,743,000350,000
Net income
2m
P
5,827,00015,955,000-2,814,0000-6,286,3583,863,000-6,059,490-480,890-3,734,0006,563,000-14,480,000-33,995,000-33,995,0001,947,700
CFO
-9m
L+1.91%
-5,313,000-4,044,000-7,005,0000-8,429,912-7,559,368-8,308,659-6,002,000-12,444,907-8,414,660-9,886,758-6,343,000-8,836,000-9,005,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

The Trendlines Group Ltd. is a private equity and venture capital firm focused on commercializing innovative technologies. They specialize in early-stage investments, ranging from incubation and seed funding to start-up and even later-stage venture capital for more established companies. Their investment strategy targets high-growth sectors such as food, medical technology (medtech), clean technology, agrifood, agritechnology, and life sciences, specifically emphasizing medical devices, biotechnology, and pharmaceuticals. They also consider opportunities in security, general medical fields, and information technology. The firm primarily seeks to invest in companies located in Israel and Singapore. Beyond financial backing, Trendlines offers extensive support to entrepreneurs, encompassing business incubation, market strategy development, research and development guidance, commercialization services, business development, funding strategies, administrative assistance, and marketing communications. The preferred exit routes for their investments include mergers and acquisitions, public stock listings, or other strategic dispositions of holdings. To mitigate the risks inherent in developing new businesses, Trendlines leverages its own capital alongside government funding. The firm actively participates in all aspects of its portfolio companies, from technological innovation to comprehensive business construction. Founded in 1993, The Trendlines Group Ltd. is headquartered in M.P. Misgav, Israel, and maintains additional offices in Tel Aviv, Israel; Beijing, China; and Singapore.

Key people

Steve Rhodes
Chairman of the Board, Chief Executive Officer
Haim Brosh
Chief Financial Officer, Joint Company Secretary & Compliance Officer · since 2018
Nir Goldenberg
Chief Executive Ofcer - Trendlines Labs · since 2019
Eric Loh
Chief Executive Officer of Trendlines Medical Singapore · since 2016
Barak Singer
Chief Executive Ofcer - Trendlines Incubators Israel Ltd. · since 2019
Yosef Hazan
Vice President & Chief Executive Officer - Trendlines Labs
Nitza Kardish
Vice President at the Company & Chief Executive Officer of Trendlines Incubators Israel · since 2016
Lay Hong Tan
Joint Company Secretary · since 2019
Stephen Philip Haslett
Independent Director · since 2015
Stephen Philip Haslett
Independent Director · since 2015
IPO date
Nov 26, 2015
Employees
39
Domiciled in
IL
Incorporated in
IL
Legal address
17 T'HELET STREET
MISGAV BUSINESS PARK
KARMIEL, Z 20174
IL
Headquarters
17 T'HELET STREET
MISGAV BUSINESS PARK M.P. MISGAVE
KARMIEL, Z 20174
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT